Announcements Trials
Browse Landscape

Phase

Phase 3 5Phase 4 1Phase 2/3 1

Status

Recruiting 2Not yet recruiting 2Completed 2Enrolling by invitation 1

Sponsor Class

INDUSTRY 7

Study Type

Interventional 7Observational 1

Sponsor

Conditions

Myasthenia Gravis 7

Interventions

pembrolizumab 1258Specimen Handling 864Carboplatin 824Magnetic Resonance Spectroscopy 806Cyclophosphamide 798Cisplatin 719Nivolumab 660Paclitaxel 635Gemcitabine 570Radiotherapy 570Biopsy 526Bevacizumab 467Dexamethasone 441fludarabine 403Docetaxel 375venetoclax 369Oxaliplatin 363Capecitabine 355Fluorouracil 354atezolizumab 337Rituximab 333durvalumab 332Doxorubicin 316Pemetrexed 306Radiosurgery 304Drug Therapy 300Ipilimumab 296Standard of Care 288Etoposide 283Radiation 277

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

7 trials
RecentStart dateEnrollment
Interventional × rozanolixizumab × 1 year × Clear all
NCT07246564 2026-05-22

Phase 4 Study Evaluating Efficacy and Safety of Rozanolixizumab in Adult Chinese Participants With Generalized Myasthenia Gravis

UCB Pharma

Phase 4 Recruiting
40 enrolled

Myasthenia Gravis

NCT06149559 2026-05-08

roMyG

UCB Pharma

Phase 2/3 Recruiting
12 enrolled

Myasthenia Gravis

NCT06540144 2026-05-08

An Extension Study Evaluating 6-week Treatment Cycles of Rozanolixizumab in Pediatric Study Participants With Generalized Myasthenia Gravis

UCB Pharma

Phase 3 Enrolling by invitation
12 enrolled

Myasthenia Gravis

NCT07463521 2026-03-17

MyVision

UCB Pharma

Phase 3 Not yet recruiting
120 enrolled

Myasthenia Gravis

NCT07465289 2026-03-11

A Study to Evaluate The Long-Term Safety And Efficacy of Rozanolixizumab in Adult Participants With Ocular Myasthenia Gravis

UCB Pharma

Phase 3 Not yet recruiting
100 enrolled

Myasthenia Gravis

NCT03971422 2025-12-24

A Study to Test Efficacy and Safety of Rozanolixizumab in Adult Patients With Generalized Myasthenia Gravis

UCB Pharma

Phase 3 Completed
200 enrolled 20 charts

Myasthenia Gravis

NCT05681715 2025-11-06

A Phase 3, Open-label, Crossover Study to Evaluate Self-administration of Rozanolixizumab by Study Participants With Generalized Myasthenia Gravis (gMG)

UCB Pharma

Phase 3 Completed
62 enrolled 11 charts

Myasthenia Gravis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡